x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0231224
| Product Information | |
|---|---|
| CAS No. | 73069-14-4 |
| Formula | C15H20O2 |
| Molecular Weight | 232.32 |
| SMILES | CC1=C2CC3C(=C)CCCC3(C)CC2OC1=O |
| Product Description | Atractylenolide II has antimelanoma effect by inhibiting STAT3 signalling. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation ,ERK and Akt inactivation, p53 dependent. Atractylenolide II can inhibit platelets activities and thrombus formation. Atractylenolide II has antiinflammatory activity. |
| Format & Storage | |
|---|---|
| Purity | > 98% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
